Month: April 2021

Montrouge, France, April 2, 2021DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced today the provisional appointment of Mr. Timothy E. Morris, as director, by the DBV Board of Directors, effective March 30, 2021. Mr. Morris will serve as a member of the Audit Committee of the Board. With this addition, the Board comprises nine directors. “We are pleased to welcome Tim Morris as a new director to the DBV Board,” said Michel de Rosen, Chairman of DBV Technologies’ Board of Directors. “Tim brings to DBV more than 20 years of leadership experience in the biopharma sector and he is highly regarded for his finance and commercial capabilities. We believe he will add tremendous...

Montrouge, France, 2 avril (22 h 30 CEST), 2021DBV Technologies annonce la nomination de Timothy E. Morris au conseil d’administration DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), une société biopharmaceutique au stade clinique, a annoncé aujourd’hui la nomination provisoire de M. Timothy E. Morris en tant qu’administrateur, par le conseil d’administration de DBV, à compter du 30 mars 2021. M. Morris sera membre du comité d’audit du conseil d’administration. Avec l’arrivée de M. Morris, le conseil d’administration sera composé de neuf administrateurs. « Nous sommes heureux d’accueillir Tim Morris en tant que nouvel administrateur au sein du conseil d’administration de DBV », a déclaré Michel de Rosen, président du conseil d’administration de DBV Technologies....

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation at the Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) held April 9-11, 2021. ProQR’s presentation Presentation title: A different type of genetic therapy: correcting a defective gene using antisense oligonucleotide treatment in CEP290 p.Cys998X LCAPresenter: Arlene V. Drack, MD, Ronald Keech Professor of Pediatric Genetic Eye Disease Department of Ophthalmology and Visual Sciences, University of IowaPresentation type: Oral paper presentationDate: April 10, 2021 at 1:23pm EDT. The presentation will be available...

SOUTH SAN FRANCISCO, Calif., April 02, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to CK-3773274 (CK-274), including data regarding its discovery and key optimization parameters, will be presented at the American Chemical Society Spring 2021 Virtual Meeting, taking place online from April 5, 2021 to April 30, 2021. Session Title: First Time DisclosuresPresentation Title: Discovery of CK-274: A novel, small molecule, cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathies (HCM)Presenter: Grace (Chihyuan) Chuang, Ph.D., Director, Medicinal Chemistry, CytokineticsDate: Friday, April 9, 2021Time: 11:05 AM – 11:45 AM PT About Cytokinetics Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class...

HONOLULU, April 02, 2021 (GLOBE NEWSWIRE) — First Hawaiian, Inc. (NASDAQ: FHB) announced today that it plans to release its first quarter 2021 financial results on Friday, April 23, 2021 before the market opens.   First Hawaiian will host a conference call to discuss the company’s results on the same day at 1:00 p.m. Eastern Time (7:00 a.m. Hawaii Time). To access the call, participants should dial (844) 452-2942 (US/Canada), or (574) 990-9846 (International) ten minutes prior to the start of the call and enter the conference ID: 4277629. A live webcast of the conference call, including a slide presentation, will be available at the following link:   www.fhb.com/earnings.   The archive of the webcast will be available at the same location. A telephonic replay of the conference call will be available approximately two hours after...

Basking Ridge, NJ, April 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Timber Pharmaceuticals, Inc. (NYSE American: TMBR) (“Timber” or the “Company”), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that its Annual Meeting of Shareholders will be held at 1:00 pm EDT on Thursday, June 3, 2021 (the “Annual Meeting”).  The Company has established April 12, 2021 as the record date for the Annual Meeting.   Meeting materials with details on the location of the Annual Meeting will be mailed to shareholders on or about April 23, 2021.   The Company also advised that its audited consolidated financial statements for the fiscal year ended December 31, 2020, included in the Company’s Annual Form on Form 10-K, contained...

RESEARCH TRIANGLE PARK, N.C., April 02, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 46,300 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Inducement Plan”). The stock options were granted as an inducement material to the new employee’s becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of G1 (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with G1, pursuant to Rule 5635(c)(4) of the Nasdaq Listing...

CALGARY, Alberta, April 02, 2021 (GLOBE NEWSWIRE) — Jura Energy Corporation (“Jura” or the “Company”) announces today the grant of restricted share units (“RSUs”) under the Company’s amended and restated restricted share unit plan (the “RSU Plan”) which was approved by shareholders on May 31, 2019. Jura granted an aggregate of 328,762 RSUs to certain of its non-executive directors in settlement of a portion of their directors’ compensation for the quarters ended June 30, 2020, September 30, 2020, December 31, 2020 and March 31, 2021. The RSUs vest as to one third on each of the first, second and third anniversaries of their date of grant. Each RSU entitles the holder to acquire one common share of the Company by delivering an exercise notice in accordance with the RSU Plan. The Company has granted an aggregate of 1,550,515 RSUs...

DUBLIN, Ireland, April 02, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 106,000 ordinary shares of Nabriva Therapeutics as an inducement to two newly-hired employees. These grants included a non-statutory option to purchase 100,000 ordinary shares of Nabriva Therapeutics awarded to Daniel Dolan, Nabriva’s newly appointed Chief Financial Officer. Both awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires’ employment compensation. The stock options were granted effective March 31, 2021 with an exercise price of $1.66 per share, which is...

SAN FRANCISCO, April 02, 2021 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the “Company” or “Kalytera“) today announced that the Company has changed its name to Claritas Pharmaceuticals, Inc. The decision to rename the Company signals the re-launch of the Company, and its intent to focus on the development of its proprietary drug, R-107, for the treatment of vaccine-resistant strains of COVID-19 as well as other viral infections. R-107 is a nitric oxide-releasing molecule designed to treat vaccine-resistant COVID-19 infection as well as the viruses that cause influenza and the common cold. The Company’s ticker symbol will change as a result of the name change. The new ticker symbol will be CLAS, pending final approval of the TSX Venture Exchange which is anticipated...